January 12, 2006 – Mylan Labs out-licensed its beta blocker Nebivolol to Forest Labs for $75 million upfront, plus milestones and royalties; Shire Pharma spun off its product formulation and development business into Supernus Pharma, an independent entity; Favrille was awarded Fast Track status for its cancer drug candidate FavID; Guidant recommended its shareholders approve a merger with Johnson and Johnson after JNJ increased its bid; Elite Pharma signed a deal with generic drug manufacturer Orit; AstraZeneca paid Protherics 16.3 million pounds as upfront money for its anti-sepsis drug; ZymoGenetics moved sharply higher after Jim Cramer’s touted its arthritis drug on his TV show. The Centient Biotech 200™ moved 44 points lower to end the day at 4002.39, a drop of 1.09%. More details...
